Jenburkt Pharmaceuticals Q3 FY24 Results Live: Profit Falls by 0.54% YoY


Jenburkt Pharmaceuticals declared their Q3 FY24 results on 06 Feb, 2024. The topline increased by 3.16% & the profit decreased by 0.54% YoY. As compared to the previous quarter, the revenue declined by 6.87% and the profit decreased by 26.19%.

The Selling, general & administrative expenses rose by 6.1% q-o-q & increased by 10.61% Y-o-Y.

The operating income was down by 22.89% q-o-q & increased by 2.64% Y-o-Y.

The EPS is 12.25 for Q3 FY24, which increased by 3.46% Y-o-Y.

Jenburkt Pharmaceuticals has delivered -11% return in the last 1 week, 5.64% return in the last 6 months, and 14.67% YTD return.

Currently, Jenburkt Pharmaceuticals has a market cap of 344.19 Cr and a 52wk high/low of 925 & 572.6 respectively.

Jenburkt Pharmaceuticals Financials

Period Q3 FY24 Q2 FY24 Q-o-Q Growth Q3 FY23 Y-o-Y Growth
Total Revenue 35.66 38.29 -6.87% 34.57 +3.16%
Selling/ General/ Admin Expenses Total 11.56 10.89 +6.1% 10.45 +10.61%
Depreciation/ Amortization 0.63 0.59 +6.48% 0.58 +7.73%
Total Operating Expense 29.09 29.78 -2.29% 28.17 +3.28%
Operating Income 6.57 8.51 -22.89% 6.4 +2.64%
Net Income Before Taxes 7.84 9.54 -17.82% 7.76 +1.08%
Net Income 5.4 7.32 -26.19% 5.43 -0.54%
Diluted Normalized EPS 12.25 16.59 -26.16% 11.84 +3.46%

FAQs

Question : What is the Q3 FY24 profit/Loss as per company?

Ans : ₹5.4Cr

Question : What is Q3 FY24 revenue?

Ans : ₹35.66Cr

Stay updated on quarterly results with our results calendar

Here’s your comprehensive 3-minute summary of all the things Finance Minister Nirmala Sitharaman said in her Budget speech: Click to download!

Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here.
Download The Mint News App to get Daily Market Updates & Live Business News.

More
Less

Published: 09 Feb 2024, 03:09 AM IST



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *